...going into the Annual Meeting, and a doubling of the current licencees by then.

What I don't want is this to become a swing traders dream stock because that would send the wrong message to the market and institutional investors.

If, as postulated, many were awaiting the outcome of the '336 recertification, Alliacense should be able to control licensing to a regular flow, which I believe would be much better than a glut and famine situation, unless they all want to license immediately.

In the regular flow of licenses, or better, situation, I would then be looking at changes to the current BoD such that there would be at least 3 executive directors, one of whom I hope would be Goerner.

My reasoning is for the simplest of reasons:

The current BoD has adequately steered the Company to what is anticipated as meaningful revenue from the patents, with that virtually resolved, I humbly suggest that now, and only now, is there a need to have on board those who could be better experienced in articulating and expanding the "umbrella concept" in directions new.

I expect that each current non-executive BoD member is aware of their respective capabilities and will be reviewing those abilities in respect of the new direction and act accordingly. However, in the unlikely event that the status quo remains in place for the Annual Meeting, my shares will gladly be pledged in any proxy solicitation for a change. Given the number of shareholders, I estimate the costs of a proxy solicitation to be in the region of $200,000, but welcome corrections from anyone who may have researched it more fully.

.

.

Be well